Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuronetics (STIM) Total Liabilities (2016 - 2025)

Neuronetics (STIM) has disclosed Total Liabilities for 10 consecutive years, with $115.3 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 5.69% to $115.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $115.3 million through Dec 2025, up 5.69% year-over-year, with the annual reading at $115.3 million for FY2025, 5.69% up from the prior year.
  • Total Liabilities for Q4 2025 was $115.3 million at Neuronetics, up from $114.1 million in the prior quarter.
  • The five-year high for Total Liabilities was $115.3 million in Q4 2025, with the low at $50.3 million in Q1 2021.
  • Average Total Liabilities over 5 years is $72.1 million, with a median of $58.0 million recorded in 2022.
  • The sharpest move saw Total Liabilities fell 3.1% in 2021, then skyrocketed 76.26% in 2025.
  • Over 5 years, Total Liabilities stood at $56.0 million in 2021, then grew by 6.74% to $59.8 million in 2022, then surged by 36.47% to $81.6 million in 2023, then skyrocketed by 33.64% to $109.1 million in 2024, then grew by 5.69% to $115.3 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $115.3 million, $114.1 million, and $103.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.